4 undervalued growth stocks worthy of deep consideration!

Dr James Fox details several highly-rated growth stocks with significant potential, all of which he’s been watching closely.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A pastel colored growing graph with rising rocket.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Growth stocks are shares of companies that are expected to expand and increase their earnings at an above-average rate compared to others in the market.

Investors are drawn to growth stocks for their potential for capital appreciation, as the companies typically reinvest their profits into further expansion rather than paying significant dividends.

So here are four growth stocks, all with attractive valuations, I’ve been keeping an eye on.

Spero Therapeutics

Spero Therapeutics is a biopharmaceutical company focused on developing innovative treatments for serious and life-threatening bacterial infections. It specialises in creating novel antibiotics and therapies to address antibiotic-resistant bacteria, addressing a critical need in healthcare.

With a market-cap of just $67m, the stock looks particularly attractive with a net cash position of $87m. Why? As the net cash position is greater than the market cap, it suggests the market could be missing something as it doesn’t have a positive valuation regarding the products in development.

Among several deals with pharma companies, Spero could receive up to $550m in pipeline payments from GSK. While there’s plenty of risk in this sector, (individual products might come to nothing), the pipeline is varied and offers some diversification.

Source: Spero Therapeutics

Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company that focuses on developing transformative treatments for severe neurological diseases.

It specialises in using adeno-associated virus (AAV) technology to deliver gene therapies to address conditions such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

The company saw significant growth in Q1 following partnerships with Novartis and Neurocrine Biosciences, but the share price has since dipped.

Pre-stage trials highlighted favourable biophysical characteristics and strong activity in mouse models, however investors may have to wait a couple years before hard clinical data gives us a better idea of the company’s prospects.  

With a market-cap of $337m, pipeline payments suggest considerable upside.

Source: Voyager Therapeutics

Immueering Corporation

Immuneering Corporation is a biotechnology company that specialises in data-driven drug discovery and development. It utilises computational biology and data analysis to identify potential drug candidates and targets for various diseases, with a focus on oncology and immunology.

It recently produced positive Phase 1 data from lead asset IMM-1-104 against mutant solid tumours relating to RAS gene mutations. In fact, it recently put its neurological programmes on hold to focus on oncology.

The stock has a market-cap of $224m and $105m in cash, inferring an enterprise value around $119m. It’s operating in a risky market, but one with huge potential. At the current price — down 36% year on year — its worth consideration.

Source: Immuneering Corporation


Yalla is an entertainment and communications company I’ve been watching for a while. Its share price has pushed upwards in recent months, but now trades at just 2.8 times EV-to-earnings. Yalla looks phenomenally cheap compared with peers like Meta. It’s been profitable since its IPO, and currently sits on $510m of cash.

The firm has embarked on a move into the mid-hardcore gaming space in an effort to speed up revenue growth which has slowed following the pandemic. This introduces an element of risk, but one that is well covered by its net cash position.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

tRandi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. James Fox has positions in Meta Platforms. The Motley Fool UK has recommended Meta Platforms. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

What kind of return could I expect by investing £100 monthly in a Stocks and Shares ISA?

Using a Stocks and Shares ISA to avoid capital gains tax could grow a £100 monthly investment into a second…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Can strong operational momentum keep the Informa share price rising?

FTSE 100 company Informa has been performing well, but this may be just the beginning of a multi-year trend for…

Read more »

Market Movers

What’s going on with the Britvic share price?

Jon Smith flags up why Britvic's share price is surging on Friday, but believes that the company is in a…

Read more »

Cheerful young businesspeople with laptop working in office
Dividend Shares

2 super-cheap passive income shares I’m eyeing up right now

Jon Smith discusses two of his favourite passive income shares in the banking and property sectors, both featuring yields above…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Up 37.5% in just 12 months, I think this is one of the FTSE 100’s best investments

Our author says this FTSE 100 company is likely to keep on capitalising on the AI and data boom. But…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

This UK share just spiked 15% on bid news. Can we bag a quick profit?

UK share prices are having a good 2024, so far, and this one's already up 39%. Two takeover bids in…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

I’m ‘blowing a raspberry’ at Raspberry Pi shares. Here’s why

Some early investors have made great profits from Raspberry Pi shares. But our writer's questioning whether the 'easy money' has…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Dividend Shares

Here are brokers’ new price targets for Legal & General and National Grid shares

City analysts are generally very positive on National Grid shares. But they're not quite as bullish on the Legal &…

Read more »